May 2026 - Andelyn Biosciences has launched a new standardized lentiviral vector manufacturing solution designed to support scalable cell therapy development and commercialization.
The newly introduced LVV Curator® Platform extends the company's existing Curator® manufacturing framework, which has previously supported more than 100 AAV programs across clinical and commercial stages. According to the company, the platform is intended to help developers transition from research-grade lentiviral production to GMP-compliant manufacturing through a more standardized and scalable process architecture.
Photo by Talha Hassan on Unsplash
Lentiviral vectors remain a critical component of many advanced cell therapies, including CAR-T and engineered immune-cell products. However, manufacturing scalability, process consistency, and regulatory compliance continue to present challenges as more therapies move toward commercialization.
Industry analysts note that platform-based manufacturing approaches are becoming increasingly important as developers seek to reduce process variability and accelerate clinical timelines. Standardized viral vector production systems may also help improve manufacturing reproducibility and facilitate technology transfer across development stages.
Photo by Mufid Majnun on Unsplash
The launch reflects a broader trend across the cell and gene therapy industry toward industrialized manufacturing models focused on scalability, automation, and process standardization.
Sources: Andelyn Biosciences LVV Curator® Platform announcement
86 198 5711 6962 
info@hillgene.com 
English
